KRAS or HRAS mutations are detected infrequently in approximately 5% of melanoma patients, whereas NRAS mutations (NRASmut) are found in about 25% of patients, which makes NRAS the second most frequent mutation type after BRAF in melanoma [129,130,131]. This evidence concerns the gene KRAS and melanoma.